

FOR IMMEDIATE RELEASE**Johnson & Johnson Reports 2013 Third-Quarter Results:****Press Contacts:**

Ernie Knewitz
(732) 524-6623
(917) 697-2318 (M)

Al Wasilewski
(732) 524-1130
(732) 447-5918 (M)

Investor Contacts:

Louise Mehrotra
(732) 524-6491

Stan Panasewicz
(732) 524-2524

**Sales of \$17.6 Billion increased 3.1% Versus 2012 Third Quarter;
Third-Quarter EPS was \$1.04
Excluding Special Items, 2013 Third-Quarter EPS of \$1.36 increased 8.8%***

New Brunswick, NJ (October 15, 2013) – Johnson & Johnson (NYSE: JNJ) today announced sales of \$17.6 billion for the third quarter of 2013, an increase of 3.1% as compared to the third quarter of 2012. Operational results increased 4.7% and the negative impact of currency was 1.6%. Domestic sales increased 1.7%. International sales increased 4.2%, reflecting operational growth of 7.1% and a negative currency impact of 2.9%.

Net earnings ** and diluted earnings per share for the third quarter of 2013 were \$3.0 billion and \$1.04, respectively. The third quarter results included after-tax special items of approximately \$0.9 billion, primarily related to an increase in the accrual for litigation expenses, in-process research and development expense, and integration and transaction costs related to the acquisition of Synthes, Inc. Third quarter 2012 net earnings included after-tax special items of approximately \$0.6 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were \$3.9 billion and diluted earnings per share were \$1.36, representing increases of 11.3% and 8.8%, respectively, as compared to the same period in 2012.*

“Our third-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers,” said Alex Gorsky, Chairman and Chief Executive Officer. “Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations. Our investments further strengthen our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers.”

The Company increased its earnings guidance for full-year 2013 to \$5.44 - \$5.49 per share. The Company’s guidance excludes the impact of special items.

Worldwide Consumer sales of \$3.6 billion for the third quarter represented an increase of 0.8% versus the prior year consisting of an operational increase of 2.0% and a negative impact from currency of 1.2%. Domestic sales increased 0.9%. International sales increased 0.8%, which reflected an operational increase of 2.6% and a negative currency impact of 1.8%.

Positive contributors to operational results were U.S. sales of **TYLENOL**[®] and **MOTRIN**[®] analgesics; upper respiratory over the counter medicines; **AVEENO**[®] skin care products and international baby care products.

Worldwide Pharmaceutical sales of \$7.0 billion for the third quarter represented an increase of 9.9% versus the prior year with operational growth of 10.9% and a negative impact from currency of 1.0%. Domestic sales increased 7.9%. International sales increased 12.0% which reflected an operational increase of 14.0% and a negative currency impact of 2.0%.

Primary contributors to operational sales growth were **INVEGA**[®] **SUSTENNA**[®]/**XEPLION**[®] (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; **REMICADE**[®] (infliximab) and **SIMPONI**[®] (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; **STELARA**[®] (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; **VELCADE**[®] (bortezomib), a treatment for multiple myeloma; **PREZISTA**[®] (darunavir), a treatment for HIV; and sales of new products.

The strong sales results of new products include **ZYTIGA**[®] (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; **XARELTO**[®] (rivaroxaban), an oral anticoagulant; and **INVOKANA**[®] (canagliflozin) for the treatment of adults with type 2 diabetes.

During the quarter, the European Commission approved **SIMPONI**[®] (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who had an inadequate response to conventional therapy. In addition, the European Commission approved the use of **VELCADE**[®] (bortezomib) as induction therapy in combination with dexamethasone or thalidomide and dexamethasone and applies to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with hematological stem cell transplantation.

Also, during the quarter, the European Commission approved STELARA[®] (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate, and the U.S. Food and Drug Administration (FDA) approved STELARA[®] alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. Additionally, the FDA approved SIMPONI[®] ARIA[™] (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

In September, the Committee for Medical Products for Human Use of The European Medicines Agency granted a positive opinion recommending approval of INVOKANA[®] (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycemic control.

In October, we announced the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. We acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs.

Worldwide Medical Devices and Diagnostics sales of \$6.9 billion for the third quarter represented a decrease of 2.0% versus the prior year consisting of an operational increase of 0.3% and a negative currency impact of 2.3%. Domestic sales decreased 4.2%. International sales decreased 0.1%, which reflected an operational increase of 4.2% and a negative currency impact of 4.3%.

Primary contributors to operational growth were sales from Biosense Webster's electrophysiology products in the Cardiovascular Care business; joint reconstruction products in the Orthopaedics business; international sales in the Surgical Care business; and biosurgical and international sales of energy products in the Specialty Surgery business.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,700 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings ** and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

** Net earnings attributable to Johnson & Johnson.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

(This release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; the effects of a continued federal government shutdown including the FDA's ability to take new regulatory submissions and continue review of our existing submissions without delays; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be

found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

###

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

THIRD QUARTER

	2013	2012	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 7,925	7,791	1.7 %	1.7	-
Europe	4,478	3,983	12.4	8.4	4.0
Western Hemisphere excluding U.S.	1,842	1,824	1.0	8.0	(7.0)
Asia-Pacific, Africa	3,330	3,454	(3.6)	5.1	(8.7)
International	9,650	9,261	4.2	7.1	(2.9)
Worldwide	\$ 17,575	\$ 17,052	3.1 %	4.7	(1.6)

NINE MONTHS

	2013	2012	Total	Percent Change	
				Operations	Currency
	\$ 23,896	22,370	6.8 %	6.8	-
	13,631	12,342	10.4	8.6	1.8
	5,530	5,266	5.0	10.3	(5.3)
	9,900	9,688	2.2	9.2	(7.0)
	29,061	27,296	6.5	9.2	(2.7)
	\$ 52,957	\$ 49,666	6.6 %	8.1	(1.5)

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

THIRD QUARTER

	2013		2012		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 17,575	100.0	\$ 17,052	100.0	3.1
Cost of products sold	5,344	30.4	5,597	32.8	(4.5)
Selling, marketing and administrative expenses	5,314	30.2	5,228	30.6	1.6
Research and development expense	2,042	11.6	1,923	11.3	6.2
In-process research and development	178	1.0	679	4.0	
Interest (income) expense, net	87	0.5	120	0.7	
Other (income) expense, net	943	5.4	(90)	(0.5)	
Earnings before provision for taxes on income	3,667	20.9	3,595	21.1	2.0
Provision for taxes on income	685	3.9	966	5.7	(29.1)
Net earnings	2,982	17.0	2,629	15.4	13.4
Add: Net loss attributable to noncontrolling interest	-	-	339	2.0	
Net earnings attributable to Johnson & Johnson	\$ 2,982	17.0	\$ 2,968	17.4	0.5
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 1.04		\$ 1.05		(1.0)
Average shares outstanding (Diluted)	2,881.2		2,818.1		
Effective tax rate	18.7 %		26.9 %		
Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)					
Earnings before provision for taxes on income	\$ 4,831	27.5	\$ 4,525	26.5	6.8
Net earnings attributable to Johnson & Johnson	\$ 3,919	22.3	\$ 3,521	20.6	11.3
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 1.36		\$ 1.25		8.8
Effective tax rate	18.9 %		22.2 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
NINE MONTHS

	2013		2012		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 52,957	100.0	\$ 49,666	100.0	6.6
Cost of products sold	16,387	30.9	15,655	31.5	4.7
Selling, marketing and administrative expenses	15,913	30.0	15,208	30.6	4.6
Research and development expense	5,772	10.9	5,334	10.7	8.2
In-process research and development	242	0.5	1,108	2.2	
Interest (income) expense, net	292	0.6	379	0.8	
Other (income) expense, net	1,630	3.1	1,307	2.7	
Earnings before provision for taxes on income	12,721	24.0	10,675	21.5	19.2
Provision for taxes on income	2,409	4.5	2,728	5.5	(11.7)
Net earnings	10,312	19.5	7,947	16.0	29.8
Add: Net loss attributable to noncontrolling interest	-	-	339	0.7	
Net earnings attributable to Johnson & Johnson	\$ 10,312	19.5	\$ 8,286	16.7	24.5
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 3.58		\$ 2.96		20.9
Average shares outstanding (Diluted)	2,879.0		2,805.0		
Effective tax rate	18.9 %		25.6 %		
Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)					
Earnings before provision for taxes on income	\$ 15,260	28.8	\$ 14,099	28.4	8.2
Net earnings attributable to Johnson & Johnson	\$ 12,315	23.3	\$ 10,969	22.1	12.3
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 4.28		\$ 3.91		9.5
Effective tax rate	19.3 %		22.2 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

<i>(Dollars in Millions Except Per Share Data)</i>	Third Quarter		% Incr. / (Decr.)	Nine Months YTD		% Incr. / (Decr.)
	2013	2012		2013	2012	
Earnings before provision for taxes on income - as reported	\$ 3,667	3,595	2.0 %	\$ 12,721	\$ 10,675	19.2 %
Litigation expenses	872	89		1,776	758	
In-process research and development	178	679		242	1,108	
Synthes integration/transaction costs and currency related	122	165 (1)		502	622	
DePuy ASR™ Hip program	35	27		117	27	
Intangible asset write-downs	-	-		-	939	
Other	(43)	(30)		(98)	(30)	
Earnings before provision for taxes on income - as adjusted	<u>\$ 4,831</u>	<u>4,525</u>	<u>6.8 %</u>	<u>\$ 15,260</u>	<u>14,099</u>	<u>8.2 %</u>
Net Earnings attributable to Johnson & Johnson - as reported	\$ 2,982	2,968	0.5 %	\$ 10,312	8,286	24.5 %
Litigation expenses	720	70		1,419	681	
In-process research and development	126	340 (2)		168	684	
Synthes integration/transaction costs and currency related	103	135		373	593	
DePuy ASR™ Hip program	31	24		122	24	
Intangible asset write-downs	-	-		-	717	
Other	(43)	(16)		(79)	(16)	
Net Earnings attributable to Johnson & Johnson - as adjusted	<u>\$ 3,919</u>	<u>3,521</u>	<u>11.3 %</u>	<u>\$ 12,315</u>	<u>10,969</u>	<u>12.3 %</u>
Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	\$ 1.04	1.05	(1.0) %	\$ 3.58	2.96	20.9 %
Litigation expenses	0.25	0.02		0.49	0.24	
In-process research and development	0.04	0.13		0.06	0.24	
Synthes integration/transaction costs and currency related	0.04	0.05		0.13	0.21	
DePuy ASR™ Hip program	0.01	0.01		0.04	0.01	
Intangible asset write-downs	-	-		-	0.26	
Other	(0.02)	(0.01)		(0.02)	(0.01)	
Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	<u>\$ 1.36</u>	<u>1.25</u>	<u>8.8 %</u>	<u>\$ 4.28</u>	<u>3.91</u>	<u>9.5 %</u>

(1) Represents inventory step-up recorded in cost of products sold

(2) In-process research and development of \$679M offset by \$339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2013	2012	% Change			2013	2012	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ^{(2) (4)}										
BABY CARE										
US	\$ 99	104	-4.8%	-4.8%	-	\$ 308	309	-0.3%	-0.3%	-
Intl	461	460	0.2%	4.3%	-4.1%	1,402	1,373	2.1%	5.2%	-3.1%
WW	560	564	-0.7%	2.6%	-3.3%	1,710	1,682	1.7%	4.2%	-2.5%
ORAL CARE										
US	142	162	-12.3%	-12.3%	-	449	476	-5.7%	-5.7%	-
Intl	253	251	0.8%	3.2%	-2.4%	755	732	3.1%	4.8%	-1.7%
WW	395	413	-4.4%	-3.0%	-1.4%	1,204	1,208	-0.3%	0.8%	-1.1%
OTC ⁽³⁾										
US	310	263	17.9%	17.9%	-	954	801	19.1%	19.1%	-
Intl	665	653	1.8%	2.0%	-0.2%	1,995	1,949	2.4%	2.7%	-0.3%
WW	975	916	6.4%	6.5%	-0.1%	2,949	2,750	7.2%	7.4%	-0.2%
SKIN CARE										
US	404	390	3.6%	3.6%	-	1,320	1,314	0.5%	0.5%	-
Intl	520	514	1.2%	2.1%	-0.9%	1,414	1,410	0.3%	0.9%	-0.6%
WW	924	904	2.2%	2.7%	-0.5%	2,734	2,724	0.4%	0.7%	-0.3%
WOMEN'S HEALTH										
US	77	81	-4.9%	-4.9%	-	242	254	-4.7%	-4.7%	-
Intl	331	326	1.5%	4.3%	-2.8%	978	964	1.5%	4.2%	-2.7%
WW	408	407	0.2%	2.5%	-2.3%	1,220	1,218	0.2%	2.4%	-2.2%
WOUND CARE/OTHER ⁽³⁾										
US	193	214	-9.8%	-9.8%	-	626	689	-9.1%	-9.1%	-
Intl	156	163	-4.3%	-3.0%	-1.3%	501	524	-4.4%	-3.8%	-0.6%
WW	349	377	-7.4%	-6.9%	-0.5%	1,127	1,213	-7.1%	-6.8%	-0.3%
TOTAL CONSUMER										
US	1,225	1,214	0.9%	0.9%	-	3,899	3,843	1.5%	1.5%	-
Intl	2,386	2,367	0.8%	2.6%	-1.8%	7,045	6,952	1.3%	2.7%	-1.4%
WW	\$ 3,611	3,581	0.8%	2.0%	-1.2%	\$ 10,944	10,795	1.4%	2.3%	-0.9%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT ^{(2) (4)}

IMMUNOLOGY

	THIRD QUARTER		% Change		
	2013	2012	Reported	Operational ⁽¹⁾	Currency
US	\$ 1,648	1,600	3.0%	3.0%	-
Intl	695	484	43.6%	47.7%	-4.1%
WW	2,343	2,084	12.4%	13.4%	-1.0%

REMICADE

US	1,013	940	7.8%	7.8%	-
US Exports ⁽⁵⁾	291	379	-23.2%	-23.2%	-
Intl	385	272	41.5%	46.1%	-4.6%
WW	1,689	1,591	6.2%	7.0%	-0.8%

SIMPONI

US	111	93	19.4%	19.4%	-
Intl	155	92	68.5%	74.9%	-6.4%
WW	266	185	43.8%	47.0%	-3.2%

STELARA

US	233	188	23.9%	23.9%	-
Intl	137	99	38.4%	38.6%	-0.2%
WW	370	287	28.9%	29.0%	-0.1%

OTHER IMMUNOLOGY

US	-	-	-	-	-
Intl	18	21	-14.3%	-8.1%	-6.2%
WW	18	21	-14.3%	-8.1%	-6.2%

INFECTIOUS DISEASES

US	278	259	7.3%	7.3%	-
Intl	543	536	1.3%	-0.1%	1.4%
WW	821	795	3.3%	2.4%	0.9%

INCIVO

US	-	-	-	-	-
Intl	76	71	7.0%	5.3%	1.7%
WW	76	71	7.0%	5.3%	1.7%

INTELENCE

US	47	45	4.4%	4.4%	-
Intl	45	49	-8.2%	-9.2%	1.0%
WW	92	94	-2.1%	-2.6%	0.5%

PREZISTA

US	215	181	18.8%	18.8%	-
Intl	195	183	6.6%	4.4%	2.2%
WW	410	364	12.6%	11.5%	1.1%

OTHER INFECTIOUS DISEASES

US	16	33	-51.5%	-51.5%	-
Intl	227	233	-2.6%	-3.4%	0.8%
WW	243	266	-8.6%	-9.3%	0.7%

	NINE MONTHS		% Change		
	2013	2012	Reported	Operational ⁽¹⁾	Currency
\$	4,865	4,524	7.5%	7.5%	-
	1,923	1,374	40.0%	43.3%	-3.3%
	6,788	5,898	15.1%	15.9%	-0.8%
	2,909	2,712	7.3%	7.3%	-
	972	1,123	-13.4%	-13.4%	-
	1,080	800	35.0%	38.2%	-3.2%
	4,961	4,635	7.0%	7.5%	-0.5%
	292	220	32.7%	32.7%	-
	386	206	87.4%	95.3%	-7.9%
	678	426	59.2%	63.0%	-3.8%
	692	469	47.5%	47.5%	-
	395	287	37.6%	38.5%	-0.9%
	1,087	756	43.8%	44.1%	-0.3%
	-	-	-	-	-
	62	81	-23.5%	-21.4%	-2.1%
	62	81	-23.5%	-21.4%	-2.1%
	775	738	5.0%	5.0%	-
	1,831	1,600	14.4%	14.7%	-0.3%
	2,606	2,338	11.5%	11.7%	-0.2%
	-	-	-	-	-
	410	305	34.4%	36.1%	-1.7%
	410	305	34.4%	36.1%	-1.7%
	138	130	6.2%	6.2%	-
	146	135	8.1%	8.1%	0.0%
	284	265	7.2%	7.2%	0.0%
	578	507	14.0%	14.0%	-
	634	554	14.4%	14.0%	0.4%
	1,212	1,061	14.2%	14.0%	0.2%
	59	101	-41.6%	-41.6%	-
	641	606	5.8%	6.0%	-0.2%
	700	707	-1.0%	-0.8%	-0.2%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS					
	2013	2012	% Change			2013	2012	% Change			
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
NEUROSCIENCE											
US	601	678	-11.4%	-11.4%	-	1,973	2,010	-1.8%	-1.8%	-	
Intl	991	990	0.1%	4.6%	-4.5%	3,043	3,019	0.8%	4.6%	-3.8%	
WW	1,592	1,668	-4.6%	-1.9%	-2.7%	5,016	5,029	-0.3%	2.0%	-2.3%	
CONCERTA/METHYLPHENIDATE											
US	38	150	-74.7%	-74.7%	-	262	493	-46.9%	-46.9%	-	
Intl	104	104	0.0%	3.5%	-3.5%	351	337	4.2%	6.6%	-2.4%	
WW	142	254	-44.1%	-42.7%	-1.4%	613	830	-26.1%	-25.1%	-1.0%	
INVEGA											
US	82	78	5.1%	5.1%	-	229	223	2.7%	2.7%	-	
Intl	65	62	4.8%	11.0%	-6.2%	200	180	11.1%	16.9%	-5.8%	
WW	147	140	5.0%	7.8%	-2.8%	429	403	6.5%	9.1%	-2.6%	
INVEGA SUSTENNA/ XEPLION											
US	180	130	38.5%	38.5%	-	502	350	43.4%	43.4%	-	
Intl	144	82	75.6%	72.9%	2.7%	396	218	81.7%	80.1%	1.6%	
WW	324	212	52.8%	51.7%	1.1%	898	568	58.1%	57.5%	0.6%	
RISPERDAL CONSTA											
US	114	113	0.9%	0.9%	-	327	336	-2.7%	-2.7%	-	
Intl	212	238	-10.9%	-8.7%	-2.2%	670	731	-8.3%	-6.1%	-2.2%	
WW	326	351	-7.1%	-5.6%	-1.5%	997	1,067	-6.6%	-5.1%	-1.5%	
OTHER NEUROSCIENCE											
US	187	207	-9.7%	-9.7%	-	653	608	7.4%	7.4%	-	
Intl	466	504	-7.5%	-0.7%	-6.8%	1,426	1,553	-8.2%	-2.8%	-5.4%	
WW	653	711	-8.2%	-3.4%	-4.8%	2,079	2,161	-3.8%	0.1%	-3.9%	
ONCOLOGY											
US	227	145	56.6%	56.6%	-	632	371	70.4%	70.4%	-	
Intl	754	483	56.1%	57.1%	-1.0%	2,028	1,439	40.9%	42.9%	-2.0%	
WW	981	628	56.2%	57.0%	-0.8%	2,660	1,810	47.0%	48.6%	-1.6%	
VELCADE											
US	-	-	-	-	-	-	-	-	-	-	
Intl	404	327	23.5%	26.3%	-2.8%	1,136	998	13.8%	16.7%	-2.9%	
WW	404	327	23.5%	26.3%	-2.8%	1,136	998	13.8%	16.7%	-2.9%	
ZYTIGA											
US	204	136	50.0%	50.0%	-	539	349	54.4%	54.4%	-	
Intl	260	129	*	97.1%	4.5%	664	348	90.8%	89.1%	1.7%	
WW	464	265	75.1%	72.9%	2.2%	1,203	697	72.6%	71.7%	0.9%	
OTHER ONCOLOGY											
US	23	9	*	*	-	93	22	*	*	-	
Intl	90	27	*	*	-5.2%	228	93	*	*	-5.7%	
WW	113	36	*	*	-3.8%	321	115	*	*	-4.6%	

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS					
	2013	2012	% Change			2013	2012	% Change			
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
<u>TOTAL OTHER</u>											
US	795	606	31.2%	31.2%	-	2,152	1,765	21.9%	21.9%	-	
Intl	504	621	-18.8%	-18.8%	0.0%	1,607	1,986	-19.1%	-18.7%	-0.4%	
WW	<u>1,299</u>	<u>1,227</u>	5.9%	5.9%	0.0%	<u>3,759</u>	<u>3,751</u>	0.2%	0.4%	-0.2%	
<u>ACIPHEX/PARIET</u>											
US	89	80	11.3%	11.3%	-	289	280	3.2%	3.2%	-	
Intl	44	115	-61.7%	-62.0%	0.3%	152	369	-58.8%	-58.7%	-0.1%	
WW	<u>133</u>	<u>195</u>	-31.8%	-32.0%	0.2%	<u>441</u>	<u>649</u>	-32.0%	-32.0%	0.0%	
<u>PROCRIT/EPREX</u>											
US	204	198	3.0%	3.0%	-	627	634	-1.1%	-1.1%	-	
Intl	140	161	-13.0%	-14.4%	1.4%	430	502	-14.3%	-14.9%	0.6%	
WW	<u>344</u>	<u>359</u>	-4.2%	-4.8%	0.6%	<u>1,057</u>	<u>1,136</u>	-7.0%	-7.3%	0.3%	
<u>XARELTO</u>											
US	246	68	*	*	-	593	144	*	*	-	
Intl	-	-	-	-	-	-	-	-	-	-	
WW	<u>246</u>	<u>68</u>	*	*	-	<u>593</u>	<u>144</u>	*	*	-	
<u>OTHER</u>											
US	256	260	-1.5%	-1.5%	-	643	707	-9.1%	-9.1%	-	
Intl	320	345	-7.2%	-6.4%	-0.8%	1,025	1,115	-8.1%	-7.2%	-0.9%	
WW	<u>576</u>	<u>605</u>	-4.8%	-4.4%	-0.4%	<u>1,668</u>	<u>1,822</u>	-8.5%	-7.9%	-0.6%	
<u>TOTAL PHARMACEUTICAL</u>											
US	3,549	3,288	7.9%	7.9%	-	10,397	9,408	10.5%	10.5%	-	
Intl	3,487	3,114	12.0%	14.0%	-2.0%	10,432	9,418	10.8%	12.9%	-2.1%	
WW	<u>\$ 7,036</u>	<u>6,402</u>	9.9%	10.9%	-1.0%	<u>\$ 20,829</u>	<u>18,826</u>	10.6%	11.7%	-1.1%	

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2013	2012	% Change			2013	2012	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾										
<u>CARDIOVASCULAR CARE</u>										
US	\$ 196	195	0.5%	0.5%	-	\$ 598	566	5.7%	5.7%	-
Intl	305	298	2.3%	6.6%	-4.3%	945	913	3.5%	7.5%	-4.0%
WW	501	493	1.6%	4.2%	-2.6%	1,543	1,479	4.3%	6.8%	-2.5%
<u>DIABETES CARE</u>										
US	237	328	-27.7%	-27.7%	-	779	1,017	-23.4%	-23.4%	-
Intl	320	301	6.3%	6.5%	-0.2%	967	955	1.3%	2.2%	-0.9%
WW	557	629	-11.4%	-11.3%	-0.1%	1,746	1,972	-11.5%	-11.0%	-0.5%
<u>DIAGNOSTICS</u>										
US	222	256	-13.3%	-13.3%	-	711	767	-7.3%	-7.3%	-
Intl	237	257	-7.8%	-2.8%	-5.0%	708	772	-8.3%	-4.1%	-4.2%
WW	459	513	-10.5%	-8.0%	-2.5%	1,419	1,539	-7.8%	-5.7%	-2.1%
<u>INFECTION PREVENTION/OTHER</u>										
US	91	98	-7.1%	-7.1%	-	271	313	-13.4%	-13.4%	-
Intl	129	134	-3.7%	4.3%	-8.0%	395	393	0.5%	6.9%	-6.4%
WW	220	232	-5.2%	-0.5%	-4.7%	666	706	-5.7%	-2.1%	-3.6%
<u>ORTHOPAEDICS</u>										
US	1,232	1,242	-0.8%	-0.8%	-	3,767	2,898	30.0%	30.0%	-
Intl	1,051	1,048	0.3%	3.4%	-3.1%	3,286	2,513	30.8%	34.3%	-3.5%
WW	2,283	2,290	-0.3%	1.1%	-1.4%	7,053	5,411	30.3%	31.9%	-1.6%
<u>SPECIALTY SURGERY</u>										
US	321	308	4.2%	4.2%	-	971	971	0.0%	0.0%	-
Intl	305	289	5.5%	9.2%	-3.7%	938	900	4.2%	7.2%	-3.0%
WW	626	597	4.9%	6.7%	-1.8%	1,909	1,871	2.0%	3.4%	-1.4%
<u>SURGICAL CARE</u>										
US	587	602	-2.5%	-2.5%	-	1,695	1,797	-5.7%	-5.7%	-
Intl	947	949	-0.2%	3.9%	-4.1%	2,935	3,019	-2.8%	0.6%	-3.4%
WW	1,534	1,551	-1.1%	1.4%	-2.5%	4,630	4,816	-3.9%	-1.8%	-2.1%
<u>VISION CARE</u>										
US	265	260	1.9%	1.9%	-	808	790	2.3%	2.3%	-
Intl	483	504	-4.2%	4.9%	-9.1%	1,410	1,461	-3.5%	4.3%	-7.8%
WW	748	764	-2.1%	3.9%	-6.0%	2,218	2,251	-1.5%	3.6%	-5.1%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS										
US	3,151	3,289	-4.2%	-4.2%	-	9,600	9,119	5.3%	5.3%	-
Intl	3,777	3,780	-0.1%	4.2%	-4.3%	11,584	10,926	6.0%	10.0%	-4.0%
WW	\$ 6,928	7,069	-2.0%	0.3%	-2.3%	\$ 21,184	20,045	5.7%	7.9%	-2.2%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Reported as U.S. sales